Related Experiment Video

Updated: Oct 17, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.7K

Primary hepatic large B-cell lymphoma following direct-acting antiviral treatment for hepatitis C

Yosra Zaimi1, Myriam Ayari2, Walid Cherifi3

  • 1Hepato-gastroenterology, Charles Nicolle Hospital, Tunis, Tunisia.

BMJ Open Gastroenterology
|August 17, 2021
PubMed

Insights

Direct-acting antivirals offer effective Hepatitis C virus (HCV) treatment but may be linked to increased hepatocellular carcinoma risks. A case study highlights primary hepatic lymphoma diagnosis post-HCV treatment.

Area of Science:

  • Hepatology
  • Virology
  • Oncology

Background:

  • Hepatitis C virus (HCV) infection poses significant global health and economic challenges.
  • HCV-related liver disease is a leading cause for liver transplantation, and chronic HCV presents systemic extrahepatic manifestations, including lymphoproliferative disorders.

Observation:

  • Direct-acting antivirals (DAAs) have revolutionized HCV treatment, offering high efficacy and improved safety.
  • Despite DAA benefits, concerns have arisen regarding potential increases in hepatocellular carcinoma (HCC) cases.

Findings:

  • This report details a case of a patient with HCV-related cirrhosis.
  • The patient received direct-antiviral therapy and was subsequently diagnosed with primary hepatic lymphoma shortly after treatment completion.

Implications:

  • The findings suggest a potential, though not fully understood, association between DAA therapy and the development of primary hepatic lymphoma in HCV patients.
  • Further research is warranted to investigate the mechanisms and clinical significance of this observation in managing HCV and its complications.

Keywords:
HCVantiviral therapycirrhosislymphoma

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.0K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

695

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...